OBJECTIVE: To examine the effects of eplerenone, a selective aldosterone blocker, on cardiac function after myocardial infarction (MI) and myocardial remodelling related transcriptional factors and mRNA expression in non-infarcted myocardium. METHODS: MI was induced by ligation of the coronary artery in Wistar rats. Rats were randomly assigned to a vehicle treated group or an eplerenone treated group (100 mg/kg/day). RESULTS: At four weeks after MI, left ventricular (LV) end diastolic pressure, LV weight, and LV end diastolic dimension were increased in MI rats. Eplerenone significantly reduced the increase in LV end diastolic pressure, LV weight, and LV end diastolic dimension. In the MI rats the decreased ejection fraction indicated systolic dysfunction and the increased E wave to A wave ratio and E deceleration rate indicated diastolic dysfunction. Eplerenone significantly attenuated this systolic and diastolic dysfunction. Myocardial interstitial fibrosis, transcriptional activities of activator protein 1 and nuclear factor kappaB, and mRNA expression of monocyte chemoattractant protein 1, plasminogen activator inhibitor 1, atrial natriuretic peptide, brain natriuretic peptide, and collagen types I and III were significantly increased at four weeks after MI. Eplerenone significantly attenuated interstitial fibrosis and suppressed transcriptional activity and mRNA expression of these genes. CONCLUSIONS: When administered after MI, eplerenone prevents cardiac remodelling accompanied by systolic and diastolic dysfunction and inhibits abnormal myocardial transcriptional activities and gene expression.
OBJECTIVE: To examine the effects of eplerenone, a selective aldosterone blocker, on cardiac function after myocardial infarction (MI) and myocardial remodelling related transcriptional factors and mRNA expression in non-infarcted myocardium. METHODS: MI was induced by ligation of the coronary artery in Wistar rats. Rats were randomly assigned to a vehicle treated group or an eplerenone treated group (100 mg/kg/day). RESULTS: At four weeks after MI, left ventricular (LV) end diastolic pressure, LV weight, and LV end diastolic dimension were increased in MI rats. Eplerenone significantly reduced the increase in LV end diastolic pressure, LV weight, and LV end diastolic dimension. In the MI rats the decreased ejection fraction indicated systolic dysfunction and the increased E wave to A wave ratio and E deceleration rate indicated diastolic dysfunction. Eplerenone significantly attenuated this systolic and diastolic dysfunction. Myocardial interstitial fibrosis, transcriptional activities of activator protein 1 and nuclear factor kappaB, and mRNA expression of monocyte chemoattractant protein 1, plasminogen activator inhibitor 1, atrial natriuretic peptide, brain natriuretic peptide, and collagen types I and III were significantly increased at four weeks after MI. Eplerenone significantly attenuated interstitial fibrosis and suppressed transcriptional activity and mRNA expression of these genes. CONCLUSIONS: When administered after MI, eplerenone prevents cardiac remodelling accompanied by systolic and diastolic dysfunction and inhibits abnormal myocardial transcriptional activities and gene expression.
Authors: M Yoshiyama; K Takeuchi; A Hanatani; S Kim; T Omura; I Toda; M Teragaki; K Akioka; H Iwao; J Yoshikawa Journal: J Mol Cell Cardiol Date: 1997-01 Impact factor: 5.000
Authors: M Yoshiyama; K Takeuchi; T Omura; S Kim; H Yamagishi; I Toda; M Teragaki; K Akioka; H Iwao; J Yoshikawa Journal: Hypertension Date: 1999-04 Impact factor: 10.190
Authors: T Shioi; A Matsumori; Y Kihara; M Inoko; K Ono; Y Iwanaga; T Yamada; A Iwasaki; K Matsushima; S Sasayama Journal: Circ Res Date: 1997-11 Impact factor: 17.367
Authors: P Aukrust; T Ueland; F Müller; A K Andreassen; I Nordøy; H Aas; J Kjekshus; S Simonsen; S S Frøland; L Gullestad Journal: Circulation Date: 1998-03-31 Impact factor: 29.690
Authors: A Hanatani; M Yoshiyama; S Kim; T Omura; I Toda; K Akioka; M Teragaki; K Takeuchi; H Iwao; T Takeda Journal: J Mol Cell Cardiol Date: 1995-09 Impact factor: 5.000
Authors: Michael G Usher; Sheng Zhong Duan; Christine Y Ivaschenko; Ryan A Frieler; Stefan Berger; Günther Schütz; Carey N Lumeng; Richard M Mortensen Journal: J Clin Invest Date: 2010-08-09 Impact factor: 14.808
Authors: Rosemeire M Kanashiro-Takeuchi; Bettina Heidecker; Guillaume Lamirault; Jennifer W Dharamsi; Joshua M Hare Journal: Clin Transl Sci Date: 2009-04 Impact factor: 4.689